Getinge Interim Report April-June 2026: Good organic growth, high profitability and strong cash flow

The real positive here is not top-line growth; it is the mix. Recurring consumables and sterile-transfer demand are the pieces that can re-rate the story because they are less cyclical, less discount-prone, and carry better incremental margins than installed-base hardware. If that mix holds, the market should start looking through soft capex in adjacent life-science budgets and focus instead on higher-quality recurring revenue, which is the main second-order benefit for the stock.

The loser set is broader than the company’s direct competitors: any medtech or life-science platform leaning on customer capital spending is vulnerable if pharma stays hesitant. That creates a relative value tailwind for pure consumables and procedure-driven names versus tools-heavy franchises, especially over the next 1-3 quarters. The risk is that this quarter proves to be an inventory and timing bounce rather than a durable budget cycle inflection; if pharma ordering does not improve into the next print, the multiple support from “resilient mix” will fade quickly.

Contrarian view: consensus may be underestimating how much of the improvement is already in the base case after a strong operational quarter. If the market extrapolates too aggressively, the stock can stall even with decent numbers because the hardest part of the story is proving sustained order conversion, not celebrating one clean quarter. The key falsifier is a re-acceleration in pharma capex or, conversely, a follow-on miss in order intake for the higher-margin category next quarter; either would materially change the 1-3 month setup.